ArteraAI is a precision medicine company leveraging AI diagnostics technology to personalize treatment decisions in oncology. By combining advanced diagnostic tools, clinical data, and imaging, the company provides fast, predictive insights for cancer care. Their solutions also include AI-driven tools to improve patient communication and healthcare workflows.
ArteraAI is an innovator of artificial intelligence-based products that are able to customize cancer treatments. Their solutions provide prognostic and predictive insights to help with more precise treatment choices and, consequently, better patient outcomes by scanning through digital pathology and clinical data.
The firm, which is grounded in multimodal AI, improves the deciphering of patient data and is in partnership with doctors and drug companies to improve the quality of clinical research, treatment selection, and consequently, the whole oncology care.
| Legal Name | ArteraAI, Inc. |
| Headquarters | Los Altos, California, United States |
| Business Model | B2B, B2B2C |
| Founding Date | 2021 |
| No. of Employees | Approx 125 (As of 2025) |
The company offers the ArteraAI Prostate Test, ArteraAI Breast Test (in development), Multimodal AI (MMAI) Platform, Predictive and Prognostic Cancer Insights, Non-invasive Biopsy Analysis, Personalized Treatment Decision Support, Financial Assistance Program and CLIA-certified Laboratory Services.
| Andre Esteva | Chief Executive Officer & Co-Founder |
| Felix Feng | Co-Founder |
| Tim Showalter | Chief Medical Officer |
| Amanda Lowe | Chief Commercial Officer |
| Nathan Silberman | Chief Technology Officer |
| Laura Chang | Senior Vice President, Product |
| Pete Simchera | Vice President, Sales |
| Calvin Chao | Vice President, Medical Science |
| Erin Stewart | Vice President, Clinical Development |
| Damion Jurrens | General Counsel |
ArteraAI makes money by using its labs with CLIA certification, selling licenses for its AI software platform to medical practitioners, and providing AI tests that have gone through the regulatory approval process and are paid for by Medicare.
Client Segments: Hospitals, oncology clinics, healthcare systems, pathology labs, and pharmaceutical companies.
Target Organizations: Providers seeking AI-driven prognostic and predictive cancer testing to support treatment planning, and pharmaceutical companies conducting clinical trials that require advanced biomarker insights.
Target Geography: Primarily the United States, with growing interest from international healthcare institutions and research partners.
Client Segments: Physicians, oncology practices, cancer care networks, and digital health platforms integrating AI-powered diagnostic insights into patient care pathways.
Target Organizations: Healthcare providers looking to deliver more personalized treatment decisions to patients, supported by ArteraAI’s predictive and prognostic testing.
End Consumers: Cancer patients who receive tailored therapy recommendations based on AI-enhanced analysis of pathology and clinical data.